LVMUY-OTC 0 ACN-N -1.49 UNH-N -5.98 VALT-T 0.31 MART-T -0.14 VIDY-T 0.23 RPRX-Q 0.15
Daily Stock Opinions and Ratings
Stockchase Opinions

Pierre Bernard Neurochem NRM-T HOLD Jan 20, 2003

Has gone up quite well and may stay level for awhile.
Pierre BernardPierre Bernard
Unknown
Unlock Rating
$8.400

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

BUY

Neurochem(NRM-T)

Aug 08, 2003
Has a very strong range of products.
Michael SmedleyMichael Smedley
Owned
Unlock Rating
$12.970

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Neurochem(NRM-T)

Sep 09, 2003
Into phase 3 trial. All cashed up. Will start to be getting attention.
Peter HodsonPeter Hodson
Owned
Unlock Rating
$14.200

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Neurochem(NRM-T)

Dec 04, 2003
(A top pick Sept 9/03. Up 58%.) As a potential treatment for Alzheimer's. Good technology. Has some US financing which will get US investors interested.
Peter HodsonPeter Hodson
Owned
Unlock Rating
$22.910

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Neurochem(NRM-T)

Jan 23, 2004
(A top pick Sept 9/03. Up100 %.) Still likes. The market opportunity is so big, would still buy at this price.
Peter HodsonPeter Hodson
Owned
Unlock Rating
$29.100

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Neurochem(NRM-T)

Mar 23, 2004
Has been moving sideways which, for a biotech, is not too bad. The company has good backing. Should see considerable upside.
Michael SmedleyMichael Smedley
Unknown
Unlock Rating
$26.600

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Neurochem(NRM-T)

Jul 08, 2004
Feels it's a little pricey at these levels given where they are in the development of their program. Have some interesting programs.
Andrew McCreathAndrew McCreath
No
Unlock Rating
$28.680

Stock price when the opinion was issued

biotechnology pharmaceutical
BUY

Neurochem(NRM-T)

Jul 28, 2004
There has been a general selloff of biotech stocks. Still believe in this company.
Michael SmedleyMichael Smedley
Owned
Unlock Rating
$22.850

Stock price when the opinion was issued

biotechnology pharmaceutical
DON'T BUY

Neurochem(NRM-T)

Apr 27, 2005
Looking at his relative performer chart, it's been an underperformer. Has negative money flow. In a very clear downtrend.
Bill CarriganBill Carrigan
No
Unlock Rating
$9.160

Stock price when the opinion was issued

biotechnology pharmaceutical
SELL

Neurochem(NRM-T)

Feb 23, 2006
He likes it, the only downside is that because the Japaneese market has risen 40% over the last year, it's a bit expensive right now. He suggests going to a different fund which is not so centered on the Japaneese market.
David DriscollDavid Driscoll
Unknown
Unlock Rating
$17.600

Stock price when the opinion was issued

biotechnology pharmaceutical
COMMENT

Neurochem(NRM-T)

Jul 04, 2022
The name of the company was indistinct and this is the closest result in the data base. It is a biotech company focused on brain health. It acquired an AI company called Metro Mark. It is signing more and more deals with pharmaceutical companies for up-front and royalty payments.
Bruce Campbell (2)Bruce Campbell (2)
Unknown
Unlock Rating
N/A

Stock price when the opinion was issued

biotechnology pharmaceutical

Build our watch list

Sign in to track investments
you care about

Latest Buy Signals

CMG-N -1.58$49.87
CP-T -0.16$102.48
ATZ-T -0.93$58.46
AZN-N 0.825$68.125
SBUX-Q -1.47$80.72

Today's Top Picks

LVMUY-… 0$109.799
ACN-N -1.49$307.39
UNH-N -5.98$379.57
VALT-T 0.31$40.91
MART-T -0.14$22.76

Popular Articles

Latest Sell Signals

NVDA-Q -0.65$116.72
MCD-N -1.14$312.35
HPYT-T 0.03$9.21
RHT-X 0.005$0.215
GOOG-Q -1.5$154.25

Most Recent Experts

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Daniel Straus

Daniel Straus

National Bank Financial

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica